Peroxidase Inhibitors
2 drugsAbout Peroxidase
Peroxidases are a family of enzymes catalyzing oxidation reactions using peroxides as electron acceptors. They participate in biological processes like oxidative stress response, detoxification, and hormone biosynthesis.
Peroxidases are potential therapeutic targets due to their involvement in various disease mechanisms. Currently, there is no genetic evidence directly linking peroxidase activity to specific diseases.
Two FDA-approved drugs, SELENIOUS ACID and MULTRYS, target peroxidases, both are small molecules. These drugs are marketed by AM REGENT for other indications.
Top Peroxidase Drugs
AM REGENT is the only company with approved drugs targeting peroxidases.
The market is highly concentrated, suggesting high barriers to entry or a lack of perceived opportunity for other players.
Peroxidase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Peroxidase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide differentiation and novel therapeutic approaches.
Peroxidase Clinical Trials 45 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on Peroxidase. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 4 | 3 | 1 | 0 | 75% |
| Phase 2 | 15 | 11 | 0 | 4 | 100% |
| Phase 3 | 11 | 9 | 0 | 2 | 100% |
| Phase 4 | 15 | 12 | 2 | 1 | 86% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Peroxidase Drug Approval Timeline (2020 - 2020)
The first drug was approved in 2019, and the most recent in 2020.
The short approval span suggests a nascent field with potential for further innovation, but also limited clinical validation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 2 companies competing
- • Market share by company
Full Drug Portfolio
- • All 2 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 2-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 38 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on Peroxidase. A trial counts if an approved drug acting on Peroxidase is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.